Post by tyson on Apr 20, 2015 11:07:03 GMT -5
I hate CK-MB. I hate it when I just order a trop and the admitting doc asks me what the CK-MB is. How often do we see an elevated CK-MB with normal serial trops? All the time.
I get that there might be some slight utility when patient had recent cath and has chest pain (troponin released in 2-3 hours, peaks at 12 hours, resolves in 7 day. CK-MB is realeased in a couple hours, peaks at 12 hours and resolves in 2-3 days). But even then, EKG and hx is going to guide you.
Below is support for this stance.
1. Do we still need to send CK-MB’s when testing for ACS?
Le RD, Kosowsky JM, Landman AB, et al. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015;33(1):72–5. PMID: 25455047.
Summary:
Troponin (TN) testing has become standard
Correlates with prognosis
Incorporated into the universal definition of myocardial infarction
CK-MB was removed from cardiac lab panel at large academic medical center (BWH)
CK-MB could still be ordered manually by physicians
Data collected during a 12 month period (6 months pre- & post-removal of CK-MB from panel)
Specimens with normal TN’s, but elevated CK-MB and CK-MB indexes were considered discrepant, and independently reviewed by 2 ED physicians for presence of ACS and documentation of final diagnosis
Of 6444 cases included in the analysis, only 17 were discrepant
Of all 17 cases, no patients were diagnosed with ACS
Removal of CK and CK-MB from the panel translated to ~ $47,000 in savings
Conclusions:
CK-MB can be removed from the routine ED cardiac panel without adversely affecting patient care. Substantial cost savings can be achieved by reducing unnecessary CK-MB and associated CK orders.
I get that there might be some slight utility when patient had recent cath and has chest pain (troponin released in 2-3 hours, peaks at 12 hours, resolves in 7 day. CK-MB is realeased in a couple hours, peaks at 12 hours and resolves in 2-3 days). But even then, EKG and hx is going to guide you.
Below is support for this stance.
1. Do we still need to send CK-MB’s when testing for ACS?
Le RD, Kosowsky JM, Landman AB, et al. Clinical and financial impact of removing creatine kinase-MB from the routine testing menu in the emergency setting. Am J Emerg Med. 2015;33(1):72–5. PMID: 25455047.
Summary:
Troponin (TN) testing has become standard
Correlates with prognosis
Incorporated into the universal definition of myocardial infarction
CK-MB was removed from cardiac lab panel at large academic medical center (BWH)
CK-MB could still be ordered manually by physicians
Data collected during a 12 month period (6 months pre- & post-removal of CK-MB from panel)
Specimens with normal TN’s, but elevated CK-MB and CK-MB indexes were considered discrepant, and independently reviewed by 2 ED physicians for presence of ACS and documentation of final diagnosis
Of 6444 cases included in the analysis, only 17 were discrepant
Of all 17 cases, no patients were diagnosed with ACS
Removal of CK and CK-MB from the panel translated to ~ $47,000 in savings
Conclusions:
CK-MB can be removed from the routine ED cardiac panel without adversely affecting patient care. Substantial cost savings can be achieved by reducing unnecessary CK-MB and associated CK orders.